Management Team

Chad Hellmann

MBA, Capital Strategy - Advisor

Mr. Hellmann is currently the CFO and co-portfolio manager at Arcus Ventures, an oncology-focused private and public market investment firm. During his tenure with Arcus, Mr. Hellmann also spent a year as the interim CFO of NLS Pharmaceutics, AG, a Swiss-based, Nasdaq-listed, late-stage clinical development CNS company where he successfully removed two Nasdaq listing deficiency issues while transitioning the investor base to fundamental holders.  Mr. Hellmann’s 25-year investment career on the buy-side has spanned the spectrum of private equity, venture capital, private debt, and public capital markets with over 15 of those years focused on the oncology sector. From 2004 through 2011, Mr. Hellmann served as CFO of an SFO and a partner of a private equity spin-off fund focused on technology, biotech and cleantech companies in the private and public markets.  After obtaining his MBA, Mr. Hellmann spent two years at UBS Warburg in investment banking.

Akseli Hemminki

MD, PhD, eMBA, Founder & CEO and Member of the Board of Directors

Aino Kalervo

MSc, MS, Chief Operating Officer

John Goldfinch

MBA, CRM, US Clinical Lead & CEO - TILT Biotherapeutics LLC

Suvi Sorsa

PhD, VP of Clinical Affairs

Tuija Keinonen

PhD, Prof, Chair of the Board of Directors, Chief Regulatory Officer

Kari Varkila

MD, PhD, MBA, Chief Medical Officer

Víctor Cervera-Carrascón

PhD, VP of Business Development

Hanna Kirk

MSc, VP of Product Development

Riikka Havunen

PhD, VP of Operations